Jolanta Weglowska: Influence Statistics

Jolanta Weglowska

Jolanta Weglowska

for the IXORA-PEDS Investigators | Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław (J.W.), and Lubelskie Centrum Diagnostyczne, Świdnik (T.B.) — both in Poland

Jolanta Weglowska: Expert Impact

Concepts for which Jolanta Weglowska has direct influence: Week patients , Brodalumab patients , Patients brodalumab , Phase 3 studies , Placebo week , Brodalumab placebo , Plaque psoriasis .

Jolanta Weglowska: KOL impact

Concepts related to the work of other authors for which for which Jolanta Weglowska has influence: Plaque psoriasis , Psoriatic arthritis , Monoclonal antibodies , Brodalumab patients , Th17 cells , Biologic agents , Atopic dermatitis .

KOL Resume for Jolanta Weglowska

Year
2022

for the IXORA-PEDS Investigators

2015

Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław (J.W.), and Lubelskie Centrum Diagnostyczne, Świdnik (T.B.) — both in Poland

Prominent publications by Jolanta Weglowska

KOL-Index: 20967 . BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis. METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ...
Known for Brodalumab Patients | Placebo Week | Phase 3 Studies | Ustekinumab Psoriasis

Key People For Week Patients

Top KOLs in the world
#1
Paul Emery
rheumatoid arthritis ankylosing spondylitis radiographic progression
#2
Josef Sebastian Smolen
rheumatoid arthritis systemic lupus erythematosus radiographic progression
#3
Désirée M F M van der Heijde
rheumatoid arthritis ankylosing spondylitis radiographic progression
#4
Maxime R DOUGADOS
rheumatoid arthritis ankylosing spondylitis desir cohort
#5
Arthur F Kavanaugh
psoriatic arthritis celgene corporation week patients
#6
Philip J Mease
psoriatic arthritis eli lilly novartis pfizer

for the IXORA-PEDS Investigators | Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław (J.W.), and Lubelskie Centrum Diagnostyczne, Świdnik (T.B.) — both in Poland